RIPK2 Antibody (Nick-1) - BSA Free
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-97631
Key Product Details
Species Reactivity
Human
Applications
Western Blot
Label
Unconjugated
Antibody Source
Monoclonal Rat IgG2A Clone # Nick-1
Format
BSA Free
Concentration
1.0 mg/ml
Product Specifications
Immunogen
Recombinant human RIP2 (receptor-interacting protein 2) (aa 1-322).
Clonality
Monoclonal
Host
Rat
Isotype
IgG2A
Scientific Data Images for RIPK2 Antibody (Nick-1) - BSA Free
Western Blot: RIPK2 Antibody (Nick-1)BSA Free [NBP1-97631]
Western Blot: RIPK2 Antibody (Nick-1) [NBP1-97631] - Detection of endogenous human RIP2 in different human cell lines by the MAb to RIP2 (Nick-1). Method: Total cell extracts (50ug) from Jurkat (lane1), THP-1 (lane 2) and HT1080 (lane 3) cell ljnes were run on a SDS-gel, and revealed with MAb to RIP2 (Nick-1) (1:1000 in 5% milk powder) for 1 hour at rooom temperature followed by incubation with HRP-coupled anti-rat secondary antibody (1:4000).Applications for RIPK2 Antibody (Nick-1) - BSA Free
Application
Recommended Usage
Western Blot
1:100-1:2000
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
PBS
Format
BSA Free
Preservative
0.02% Sodium Azide
Concentration
1.0 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: RIPK2/RIP2
Long Name
Receptor Interacting Serine/Threonine Kinase 2
Alternate Names
CARD3, GIG30, RICK, RIP-2, RIP2
Gene Symbol
RIPK2
Additional RIPK2/RIP2 Products
Product Documents for RIPK2 Antibody (Nick-1) - BSA Free
Product Specific Notices for RIPK2 Antibody (Nick-1) - BSA Free
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...